Is your IP strategy working with complete information or flying blind?
Most pharma IP teams believe their search and analytics processes are robust. But three critical intelligence gaps are silently undermining portfolio decisions, competitive positioning, and R&D investment.
THE PROBLEM
The 3 intelligence gaps costing pharma IP teams the most
These aren’t edge cases. They show up consistently across mid-size and large pharma organizations, often undetected until a costly decision has already been made.
GAP 01
Incomplete landscape coverage
Keyword-based searches miss Markush structures, sequence variants, and non-patent literature, leaving substantial prior art undiscovered. In pharma, an unchecked compound variant can invalidate an entire prosecution strategy.
GAP 02
Reactive competitive monitoring
Most teams learn about competitor filings weeks or months after the fact. Without real-time watch services and prosecution alerts, you’re responding to the landscape instead of shaping it.
GAP 03
Disconnected analytics and decision-making
Search outputs rarely flow into actionable portfolio insights. IP data stays siloed from R&D, business development, and licensing decisions, reducing its strategic value at every level.
HOW LEADERS ARE RESPONDING
What leading pharma IP organizations do differently
Top-performing IP teams aren’t working harder; they’ve restructured how intelligence is gathered, interpreted, and acted on.
Structure- and sequence-first search
Moving beyond keyword searches to chemical structure, Markush group, and biological sequence methodologies that surface what standard tools miss.
Continuous competitive intelligence
Automated prosecution alerts and competitor watch services that surface relevant filings, continuations, and claim amendments in near real time.
Analytics connected to strategy
Custom dashboards and white space analyses that translate raw patent data into portfolio gaps, licensing opportunities, and R&D prioritization signals.
Integrated expert + technology model
Combining expert IP analysts with AI-powered tools, not one or the other, to reduce turnaround time without sacrificing analytical depth.
THE MAXVAL MODEL
What an optimized search + analytics model looks like
MaxVal’s pharma IP search and analytics service is built around a four-layer model that closes each intelligence gap from initial search to boardroom-ready insight.
01. Comprehensive multi-methodology search
Every engagement covers prior art, FTO, validity, and landscape through keyword, structure, sequence, and NPL searches executed by a team with 500+ years of collective IP experience across pharma, biotech, and medical devices.
02. Real-time competitive watch
Prosecution alerts, company/inventor watch, and technology monitoring keep your team informed of developments as they happen, not after quarterly reviews.
03. Custom analytics and white space mapping
Tailored taxonomy frameworks and landscape reports identify where competitors are consolidating, where claim space is open, and where your portfolio is most exposed.
04. Actionable intelligence, not raw data
Reports are structured for decision-makers, IP counsel, R&D heads, and C-suite stakeholders with clear findings, risk flags, and strategic recommendations, not just search results.
WHY MAXVAL
Trusted by the world's most innovative pharma and biotech organizations
For over 20 years, MaxVal has helped corporations and law firms turn IP intelligence into competitive advantage.
700+
Clients worldwide
500+
Years of collective IP expertise
20+
Years serving pharma & biotech
— IP Docketing Program Manager, Holland & Hart LLP
Close the intelligence gap in your pharma IP strategy
Speak directly with a MaxVal IP expert. In a 30-minute call, we’ll review your current search and analytics workflow and identify where the highest-impact improvements lie.
No commitment. 30 minutes. Immediate value.
© Copyright 2026 MaxVal Group, Inc. | All Rights Reserved | Terms and Conditions | Privacy Policy